
    
      This is a special drug use surveillance on long-term use of alogliptin with a 1-year
      (12-month) observational period, designed to investigate the safety and efficacy of long-term
      combination therapy with alogliptin and sulfonylurea in participants with type 2 diabetes
      mellitus in a routine clinical setting.

      Participants with type 2 diabetes mellitus who responded inadequately to treatment with
      sulfonylurea in addition to diet therapy and exercise therapy will be enrolled in this study.
      The planned sample size is 1,000.

      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
    
  